Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

153.58 -1.40 (-0.90%)
Streaming Delayed Price Updated: 10:59 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
51 52 Next >
News headline image
A Bull Market Is Coming: Load Up On These 3 Cheap Stocks Today ↗
These stocks are all trading at less than 12 times their future profits. 
Via The Motley Fool
News headline image
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years?
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? 
Via News Direct
News headline image
Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients ↗
 
Via Benzinga
News headline image
What Is Autologous Cell-Based Therapy, The Treatment Revolutionizing Regenerative Medicine That Could Be Set To Explode Over The Next Few Years? ↗
Successful Autologous Cell-Based Therapies 
Via Benzinga
News headline image
Gilead Exercises First License Option Under Agreement With Nurix Therapeutics ↗
 
Via Benzinga
News headline image
Gilead Sciences Unusual Options Activity ↗
 
Via Benzinga
News headline image
A Look Into Gilead Sciences' Debt ↗
 
Via Benzinga
News headline image
Peering Into Gilead Sciences's Recent Short Interest ↗
 
Via Benzinga
News headline image
Analyst Expectations for Gilead Sciences's Future ↗
 
Via Benzinga
News headline image
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats ↗
With the COVID pandemic still ongoing, having claimed  more than 6.8 million lives from about 758 million cases and crippling the global economy, there are several reasons why drug research and... 
Via Benzinga
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
Drug Companies Raising Prices Greater Than Inflation? US Government Mulling Imposing Fines ↗
Under Joe Biden's signature Inflation Reduction Act, drugmakers for twenty-seven drugs will be penalized for charging prices that rise faster than inflation for people with disabilities or the elderly... 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks Delivering High-Dividend Yields ↗
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
News headline image
3 Stocks to Buy Right Now That Are Cash Cows ↗
If cash is king, these three stocks should wear crowns. 
Via The Motley Fool
News headline image
If You Invested $100 In This Stock 20 Years Ago, You Would Have $2,100 Today ↗
 
Via Benzinga
News headline image
Why Shares of MacroGenics Jumped Thursday ↗
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy. 
Via The Motley Fool
News headline image
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds?
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? 
Via News Direct
Topics Economy
News headline image
2 Healthcare Stocks That Could Help Set You Up for Life ↗
Even seemingly boring businesses can deliver solid returns over long periods. 
Via The Motley Fool
News headline image
Cell Therapy Has Shown Near Miraculous Remission Rates In Cancer Patients, But The Growing Industry Relies On This Company – A Uniquely Positioned Ticker In The Weeds? ↗
Cryoport Inc. (NASDAQ: CYRX) provides the life sciences industry with comprehensive supply chain solutions to support vital therapeutics. 
Via Benzinga
News headline image
Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading ↗
Over the past week, the market had a nice uptick making it harder for defensive sectors like healthcare to get traction up only 0.51% and down almost 5% YTD. 
Via Talk Markets
News headline image
Elliott Wave Technical Analysis: Gilead Inc. ↗
Looking for a clear three wave move in wave (ii) to then place longs. 
Via Talk Markets
News headline image
7 Cash-Rich Companies to Invest in During Economic Uncertainty ↗
Although they’re not necessarily the most exciting enterprises, these cash-rich stocks should keep your portfolio upright. 
Via InvestorPlace
News headline image
GSK/Pfizer-Backed ViiV Healthcare's HIV Treatment At Par With Gilead's: Study Shows ↗
 
Via Benzinga
News headline image
This Recession-Proof Company Has a Best-in-Class Dividend ↗
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group. 
Via The Motley Fool
News headline image
Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Goldman Sachs boosted the price target for Kaiser Aluminum Corporation (NASDAQ: KALU) from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum shares... 
Via Benzinga
News headline image
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers ↗
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
News headline image
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood ↗
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
News headline image
Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings ↗
Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).  
Via Benzinga
News headline image
2 Biotech Stocks That Could Make You Richer ↗
Patience will pay off with these two stocks. 
Via The Motley Fool
News headline image
Thoughts For Thursday: Risk-off, Risk-on ↗
The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible. 
Via Talk Markets
< Previous 1 2
...
29 30 31 32 33 34 35 36 37
...
51 52 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.